- Home
- LAW vs ABOS Comparison
LAW vs ABOS Comparison
Compare LAW & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LAW | ABOS |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.0M | 197.9M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LAW | ABOS |
|---|---|---|
| Price | $4.02 | $2.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $8.00 | $8.00 |
| AVG Volume (30 Days) | 230.4K | ★ 685.1K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $156,849,000.00 | N/A |
| Revenue This Year | $11.23 | N/A |
| Revenue Next Year | $10.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.29 | N/A |
| 52 Week Low | $2.45 | $1.19 |
| 52 Week High | $9.11 | $3.60 |
Technical Indicators
Market Signals| Indicator | LAW | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 54.08 | 41.30 |
| Support Level | $3.77 | $2.14 |
| Resistance Level | $4.60 | $2.43 |
| Average True Range (ATR) | 0.21 | 0.17 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 44.53 | 17.69 |
Price Performance
Historical ComparisonAbout LAW CS Disco Inc.
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.